share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  2024/08/14 02:02

Moomoo AI 已提取核心信息

BioCardia reported Q2 2024 financial results with revenue of $3,000, down from $43,000 in Q2 2023. Net loss improved to $1.6 million compared to $3.4 million in the prior year quarter, primarily due to reduced operating expenses following completion of CardiAMP Cell Therapy Heart Failure Trial enrollment in late 2023.Research and development expenses decreased to $800,000 from $2.3 million year-over-year, while selling, general and administrative costs declined to $852,000 from $1.2 million, reflecting staff reductions and lower personnel expenses. The company ended the quarter with $1.4 million in cash and cash equivalents, up slightly from $1.1 million at 2023 year-end.Management indicates current cash is insufficient to fund operations through September 2024, raising substantial doubt about continuing as a going concern. The company plans to raise additional capital through various means including a potential offering under its recently filed S-1 registration statement, though success is not assured. BioCardia must also demonstrate compliance with Nasdaq's minimum stockholders' equity requirements by September 2, 2024 to maintain listing.
BioCardia reported Q2 2024 financial results with revenue of $3,000, down from $43,000 in Q2 2023. Net loss improved to $1.6 million compared to $3.4 million in the prior year quarter, primarily due to reduced operating expenses following completion of CardiAMP Cell Therapy Heart Failure Trial enrollment in late 2023.Research and development expenses decreased to $800,000 from $2.3 million year-over-year, while selling, general and administrative costs declined to $852,000 from $1.2 million, reflecting staff reductions and lower personnel expenses. The company ended the quarter with $1.4 million in cash and cash equivalents, up slightly from $1.1 million at 2023 year-end.Management indicates current cash is insufficient to fund operations through September 2024, raising substantial doubt about continuing as a going concern. The company plans to raise additional capital through various means including a potential offering under its recently filed S-1 registration statement, though success is not assured. BioCardia must also demonstrate compliance with Nasdaq's minimum stockholders' equity requirements by September 2, 2024 to maintain listing.
BioCardia公司公布了2024年第二季度的财务结果，营业收入为3000美元，较2023年第二季度的43000美元下降。净亏损改善至160万人民币，相较于去年同期的340万人民币，主要是由于在2023年底完成CardiAMP电芯治疗心衰试验招募后，营业费用减少。研究和开发费用同比减少至80万美元，从230万人民币下降，而销售、一般及行政费用则从120万人民币下降至85.2万美元，反映出员工减少和低个人费用。公司在本季度结束时持有现金及现金等价物140万人民币，较2023年年末的110万人民币略有上升。管理层表示，目前的现金不足以维持运营至2024年9月，这对持续经营提出了重大疑问。公司计划通过各种方式筹集额外资金，包括在最近提交的S-1注册声明下进行潜在发行，尽管成功并无保证。BioCardia还必须在2024年9月2日前证明符合纳斯达克的最低股东权益要求，以维持上市。
BioCardia公司公布了2024年第二季度的财务结果，营业收入为3000美元，较2023年第二季度的43000美元下降。净亏损改善至160万人民币，相较于去年同期的340万人民币，主要是由于在2023年底完成CardiAMP电芯治疗心衰试验招募后，营业费用减少。研究和开发费用同比减少至80万美元，从230万人民币下降，而销售、一般及行政费用则从120万人民币下降至85.2万美元，反映出员工减少和低个人费用。公司在本季度结束时持有现金及现金等价物140万人民币，较2023年年末的110万人民币略有上升。管理层表示，目前的现金不足以维持运营至2024年9月，这对持续经营提出了重大疑问。公司计划通过各种方式筹集额外资金，包括在最近提交的S-1注册声明下进行潜在发行，尽管成功并无保证。BioCardia还必须在2024年9月2日前证明符合纳斯达克的最低股东权益要求，以维持上市。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Plus Therapeutics
    PSTV
    -- 2.0100
    Impact BioMedical
    IBO
    -- 1.270
    Windtree Therapeutics
    WINT
    -- 2.1000
    CervoMed
    CRVO
    -- 11.630
    Akari Therapeutics
    AKTX
    -- 1.5500
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    🎙️讨论 1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点